A (diastolic) heart failure patient may well benefit from the use of NO donors, inhibitors of cGMP-degrading enzymes, antioxidants, or other drugs that block the oxidative-stress effects on titin stiffness (Gladden et al. 2014), in that cardiomyocyte stiffness will be reduced and myocardial diastolic function improved. This evidence concerns the gene TTN and heart failure.